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Abstract
Aims/hypothesis Previous metabolomics studies suggest that type 1 diabetes is preceded by specific metabolic disturbances. The
aim of this study was to investigate whether distinct metabolic patterns occur in peripheral blood mononuclear cells (PBMCs) of
children who later develop pancreatic beta cell autoimmunity or overt type 1 diabetes.
Methods In a longitudinal cohort setting, PBMC metabolomic analysis was applied in children who (1) progressed to type 1
diabetes (PT1D, n = 34), (2) seroconverted to ≥1 islet autoantibody without progressing to type 1 diabetes (P1Ab, n = 27) or (3)
remained autoantibody negative during follow-up (CTRL, n = 10).
Results During the first year of life, levels of most lipids and polar metabolites were lower in the PT1D and P1Ab groups
compared with the CTRL group. Pathway over-representation analysis suggested alanine, aspartate, glutamate,
glycerophospholipid and sphingolipid metabolism were over-represented in PT1D. Genome-scale metabolic models of
PBMCs during type 1 diabetes progression were developed by using publicly available transcriptomics data and constrained
with metabolomics data from our study. Metabolic modelling confirmed altered ceramide pathways, known to play an important
role in immune regulation, as specifically associated with type 1 diabetes progression.
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Conclusions/interpretation Our data suggest that systemic dysregulation of lipid metabolism, as observed in plasma, may impact
the metabolism and function of immune cells during progression to overt type 1 diabetes.
Data availability The GEMs for PBMCs have been submitted to BioModels (www.ebi.ac.uk/biomodels/), under accession
number MODEL1905270001. The metabolomics datasets and the clinical metadata generated in this study were submitted to
MetaboLights (https://www.ebi.ac.uk/metabolights/), under accession number MTBLS1015.
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Abbreviations
AAG Alanine, aspartate and glutamate
metabolism
BCAA Branched chain amino acid
CCM Central carbon metabolism
Cer Ceramide
CTRL Children who remained autoantibody
negative during follow-up
DIPP Type 1 Diabetes Prediction
and Prevention
GADA GAD autoantibodies
GEM Genome-scale metabolic model
GPL Glycerophospholipid
GSMM Genome-scale metabolic modelling
IAA Insulin autoantibodies
IA-2A Insulinoma-associated
antigen-2 autoantibodies
LPC Lysophosphatidylcholine
P1Ab Children who seroconverted
to ≥1 islet autoantibody
without progressing
to type 1 diabetes during follow-up
PBMC Human peripheral blood
mononuclear cell
PC Phosphatidylcholine
PIS Pathway impact score
POA Pathway overrepresentation analysis
PT1D Children who progressed to type
1 diabetes during follow-up
RC Regression coefficient
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RM Reporter metabolite
SM Sphingomyelin
SMM Sphingolipid metabolism
sPLS-DA Sparse partial least squares discriminant
analysis
TG Triacylglycerol
UPLC-QTOFMS Ultra-performance liquid
chromatography coupled with
time-of-flight mass spectrometry
VIP Variable importance in projection
ZnT8A Zinc transporter 8 autoantibodies
Introduction
The incidence of type 1 diabetes in most Western countries
has been increasing over the past few decades, particularly
among children below 5 years of age [1]. About 70% of chil-
dren with type 1 diabetes carry increased risk-associated geno-
types in HLA loci, whereas only 3–7% of the population with
the same risk alleles develop type 1 diabetes [2].
The appearance of autoantibodies against insulin (IAA), a
65 kDa isoform of GAD (GADA), insulinoma-associated
antigen-2 (IA-2A), and/or zinc transporter 8 (ZnT8A) in the
plasma is an early sign of emerging islet autoimmunity and
clinical type 1 diabetes [3]. It is known that children with
multiple islet autoantibodies in particular have an increased
risk of type 1 diabetes [4]. In addition to genetic predisposi-
tion, other exogenous environmental factors affect risk, such
as intestinal dysbiosis, reduced gut microbial diversity [5],
level of hygiene [6] and infant-feeding regimen [7, 8] are
implicated in the initiation of beta cell autoimmunity. Our
recent data also suggest that prenatal exposure to environmen-
tal chemicals modulates lipid metabolism in newborn infants
and increases their subsequent risk of type 1 diabetes [9].
However, the early pathogenesis of type 1 diabetes is still
poorly understood and of the molecular signatures and related
pathways predictive of progression to overt type 1 diabetes
have yet to be identified.
Alterations in immune cell metabolism may affect the host
immune system [10]. In fact, external perturbation of key
metabolic processes, such as glycolysis and amino acid
metabolism, have already been shown to impair T cell activa-
tion, differentiation and cytokine production [11]. Human
peripheral blood mononuclear cells (PBMCs), including T
cells (~70%), B cells (~15%), monocytes (~5%), dendritic
cells (~1%) and natural killer (NK) cells (~10%) obtained
from healthy donors and progressors to type 1 diabetes are
already being investigated in order to better understand this
phenomenon [12]. Such efforts seek to elucidate how immune
cell metabolic processes are altered in seroconversion and
progression to overt type 1 diabetes; currently a largely
unknown area.
Metabolomics is the study of small (<1500 Da) molecules
and their functions in cells, tissues and body fluids [13]. The
metabolome, which can be seen partly as a phenotypic readout
of the genome, is sensitive to changes in immune system
status, diet and the gut microbiota [14]. Through metabolomic
analyses, we have previously shown that decreased levels of
plasma sphingomyelins (SMs) and phosphatidylcholines
(PCs) are associated with progression to type 1 diabetes
[15–17].
In this study, we applied metabolomics to determine levels
of molecular lipids and polar metabolites in PBMCs isolated
from prospective samples collected in the Type 1 Diabetes
Prediction and Prevention (DIPP) study, with the aim of eluci-
dating the events preceding the onset of islet autoimmunity
and overt type 1 diabetes. We sought to address whether
distinct metabolic patterns can be discerned during infancy
among three study groups of children: (1) those who devel-
oped clinical type 1 diabetes, (2) those who seroconverted to
at least one islet autoantibody but were not diagnosed with
type 1 diabetes during follow-up and (3) a control group, i.e.
children who remained autoantibody negative during follow-
up.
Methods
Study design and protocol In this study, the samples were
obtained from the Finnish DIPP study [18]. The DIPP study
has screened more than 230,000 newborn infants for HLA-
conferred susceptibility to type 1 diabetes in three university
hospitals: those at Turku, Tampere and Oulu in Finland [19].
The children involved in the current study were chosen from
the subset of DIPP children which were from the city of
Tampere, Finland. The study protocol was approved by the
ethics and research committee of University of Tampere and
Tampere University Hospital. The study was conducted
according to the guidelines of the Declaration of Helsinki.
Written informed consent was provided by the parents at the
beginning of the study for the children to participate in the
study. Here, longitudinal samples for each child were collect-
ed between 1998 and 2012. For each child, longitudinal
samples for PBMC metabolomic analysis were obtained at
12, 24 and 36 months of age.
This study comprises samples (n = 137 for lipidomics and
n = 134 for polar metabolites) from 71 children, divided into
three groups:: (1) 27 children who seroconverted to at least
one islet autoantibody but were not diagnosed with type 1
diabetes during the follow-up period (P1Ab), (2) 34 children
who seroconverted to more than one islet autoantibody and
subsequently developed type 1 diabetes (PT1D), and (3) ten
control children (CTRL), i.e. children who remained islet
autoantibody negative during follow-up. The three study
groups were similar in terms of HLA-associated risk for type
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1 diabetes, sex and age. Selected characteristics of the partic-
ipants involved in this study are listed in (Table 1).
HLA genotyping Screening for HLA-conferred susceptibility
to type 1 diabetes was performed using cord blood samples.
The HLA genotyping was performed using a time-resolved,
fluorometry-based assay for four alleles using lanthanide
chelate-labelled, sequence-specific oligonucleotide probes
detecting DQB1*02, DQB1*03:01, DQB1*03:02, and
DQB1*06:02/3 alleles [20]. The carriers of genotypes
DQB1*02/DQB1*03:02 or DQB1*03:02/x genotypes (here
x =DQB1*03:01, DQB1*06:02, or DQB1*06:03 alleles)
were categorised as being eligible and recruited for the DIPP
follow-up programme in Tampere until 3 years of age.
A more extensive HLA genotyping was performed for the
children participating this study. This genotyping defined all
common European HLA-DR-DQ haplotypes at low resolu-
tion and at higher resolution haplotypes where this was rele-
vant for estimation of the risk for type 1 diabetes conferred,
e.g. HLA-DR4 subtypes in DR4-DQ8 haplotypes. In a series
of 2991 family trios from the Finnish Pediatric Diabetes
Register, the genotype risks were defined and genotypes were
combined into six groups from (strongly protective) to 5 (high
risk) which did not overlap for 95% CIs of their OR values for
type 1 diabetes [21].
Detection of islet autoantibodies The children with HLA-
conferred genetic susceptibility were prospectively observed
for levels of type 1 diabetes-associated autoantibodies (ICA,
IAA, IA-2A and GADA). These autoantibodies were assayed
from plasma samples taken at each follow-up visit as previ-
ously described [22]. Levels of islet cell autoantibodies were
determined using an approved immunofluorescence assay
with a detection limit of 2.5 Juvenile Diabetes Foundation
Units (JDFU) [23]. GADA and IAA levels were quantified
using specific radiobinding assays, the threshold of positivity
being 5.36 and 3.48 relative units (RU), respectively [24, 25].
Similarly, IA-2A levels were measured with a radiobinding
assay with a threshold of 0.43 RU [26].
Analysis of molecular lipids and polar metabolites In this
study, non-fasting blood samples were collected, plasma was
prepared within 3 h of sample collection and stored at −80°C
until analysed (see electronic supplementary material [ESM]
Methods for further details). The samples were randomised
and extracted using a modified version of the previously
published Folch procedure [27, 28]. Molecular lipids were
determined using ul t ra-high-performance l iquid
chromatography-quadrupole time-of-flight mass spectrometry
(UHPLC-Q-TOF-MS). Identification of lipids was carried out
by combining MS (and retention time), MS/MS information
and a search of the LIPID MAPS spectral database (http://
www.lipidmaps.org).
For determination of polar metabolites, the samples were
derivatised using a two-step procedure. Initially the sampleswere
methoximated by incubating the samples with methoxyamine
hydrochloride (25 μL, 20 mg/ml in pyridine, Sigma-Aldrich,
Chemie, Taufkirchen, Germany) at 45°C for 1 h. N-Methyl-
N-(trimethylsilyl)trifluoroacetamide (MSTFA, 25 μl, Sigma-
Aldrich) was then added and the samples were incubated for a
further 1 h. A retention index standard containing straight chain,
even alkanes (n 10–40, 10 μl, Sigma-Aldrich) was added. The
derivatised samples were analysed using gas chromatography
(Agilent 7890B, Agilent Technologies, Santa Clara, CA, USA)
coupled to a single quad mass spectrometer (5977B). Further
details of the analysis of molecular lipids and polar metabolites
in the PBMCs, along with the data pre-processing can be found
in the ESM Methods.
Statistical methods The lipidomics and polar metabolites
datasets were divided into three study groups: CTRL, P1Ab,
and PT1D (Table 1, ESM Fig. 1). The age of the participant
was calculated as the time difference between the date the sample
waswithdrawn and the date of birth of the child. If more than two
samples from the same child matched a time interval, the closest
was selected. Each group was divided into three age groups of
12, 24 and 36 months (ESM Fig. 1). The data were log2-trans-
formed. Homogeneity of the samples was assessed by principal
component analysis (PCA) [29] and no outliers were detected
(95% CI). The log2-normalised intensities of the total identified
lipids and polar metabolites in the participants are shown in ESM
Figs 2 and 3, respectively. The differences in PBMC lipidomes
and polarmetabolites between the study groups (P1Ab vsCTRL,
PT1D vs CTRL, PT1D vs P1Ab), at 12, 24 and 36 months of
age, were explored independently by using multivariate analysis
(sparse partial least squares discriminant analysis [sPLS-DA])
[30] and univariate analysis (unpaired two-sample t test) (see
ESM Statistical Methods). The R statistical programming
language [31] was used for data analysis and visualisation.
Further details of data analysis, including pathway over-
representation analysis (POA), packages and software are
discussed in the ESM.
Meta-analysis of transcriptomics datasets and genome-scale
metabolic modelling In order to understand the regulation of
metabolic pathways in PBMCs after seroconversion and type 1
diabetes progression, genome-scale metabolic models (GEMs)
[12, 32–34] of PBMCs were developed. Gene expression or
transcriptomics datasets were used to contextualise these models
for the P1Ab, P1TD and CTRL groups. Gene expression data of
PBMCs was obtained from two related cohorts: (1) BABYDIET
[35–37], a prospective birth cohort of children being studied for
the progression to islet autoimmunity and type 1 diabetes and (2)
Diabetes-Genes, Autoimmunity and Prevention (D-GAP) study,
a prospective study that recruited children newly diagnosed with
type 1 diabetes [37]. The longitudinal study settings of these
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cohorts are similar to the DIPP study design [3]. The datasets
from these studies were downloaded from ArrayExpress (www.
ebi.ac.uk; accession number E-MTAB-1724). Expression data
for 15 non-progressors (P1Ab), 51 cases of type 1 diabetes
(PT1D), and their controls (CTRL) were selected for genome-
scale metabolic modelling (GSMM) [12, 32–34]. In addition,
differential expression of genes (DEG) for P1Ab vs CTRL,
PT1D vs CTRL and PT1D vs P1Ab groups was performed.
The p values and log2 fold changes were calculated.
A GEM for PBMCs was developed by applying the INIT
algorithm [38] on Human Metabolic Reconstruction (HMR
2.0) [39] as a template model. GEMs were contextualised/
constrained for different conditions using expression datasets.
The gene/transcript expression data obtained from PBMCs of
PT1D, P1Ab and CTRLwere employed to score each reaction
of HMR 2.0. Contextualisation and analysis of GEMs for
PBMCs are further described in the ESM.
Results
Global lipidome of immune cells in progression to islet auto-
immunity and type 1 diabetes PBMCs were isolated from chil-
dren who (1) progressed to clinical type 1 diabetes during follow-
up (PT1D, n= 34), (2) seroconverted to at least one islet autoan-
tibody butwere not diagnosedwith type 1 diabetes during follow-
up (P1Ab, n= 27) or (3) remained autoantibody negative during
follow-up (CTRL, n = 10) (Table 1). The lipidomics dataset
comprised 153 lipid species. Sources of variation in the PBMC
lipidome dataset were identified using linear regression model-
ling, where the concentrations of lipids were regressed with vari-
ous clinical variables such as age, sex, disease conditions and their
interactions. This analysis showed that the age of an individual
indeed had a confounding effect (>10% of explained variation,
EV) on the lipidome (ESMFig. 4). The effect of sex was, howev-
er, minimal (<1% EV) (ESM Fig. 4). The interactions between or
among the factors had no significant effect on the lipidome.
The results from multi- and univariate analyses suggest that
lipid levels in PBMCs from the P1Ab and PT1D groups are
different from those in PBMCs from the CTRL group (Fig.
1a). Many classes of lipids, including cholesterol esters
(CEs) , lysophosphat idy lchol ines (LPCs) , PCs ,
phosphatidylethanolamines (PEs), phosphatidylinositols
(PIs), SMs, ceramides (Cers) and triacylglycerols (TGs)
were altered (sPLS-DA: AUC ~0.65, regression coeffi-
cient [RC] (>±0.05), variable importance in projection
[VIP] scores >1 [40]) and/or (unpaired two-sample t
test: p < 0.05) between these groups (Fig. 1a).
At 12 months of age, i.e. before the median age of serocon-
version, the levels of some TG, PC, LPC and Cer species were
lower in the PBMCs of the P1Ab and PT1D groups, as compared
with those in the PBMCs of the CTRL group (Fig. 1a). At
24 months of age, there was a subtle increase or no change in
these same lipid levels in the P1Ab and PT1D groups (Fig. 1a, c,
ESM Fig. 5). This effect was most prominently seen in the P1Ab
group, where the total lipid level was higher (p= 0.048) than in
the CTRL group (Fig. 1c). Interestingly, this accumulation was
transient, as these lipids had returned to their previous (12 month
time point) levels by 36months (Fig. 1a, c). However, Cer(d18:1/
24:0) was persistently decreased in the PT1D group compared
with the P1Ab and CTRL groups (Fig. 1b). The log mean inten-
sities of selected lipids across different age groups are shown in
(ESM Fig. 5). In this analysis, time was not explicitly considered
for statistical analysis, as the follow-up samples fromall the partic-
ipants were not available at all time points.
PBMC lipidome before and after the first appearance of islet
autoantibodiesWe aimed to identify the molecular lipids that
were altered (p < 0.05) following seroconversion to islet auto-
immunity (vs before seroconversion) in both the P1Ab and
PT1D groups (Fig. 1d). Cer(d18:1/24:0) and TGs with low
carbon number and double bond count were downregulated
in PT1D after seroconversion (ESM Table 1). Total lipids in
the P1Ab group (p = 6 × 10−5) and PT1D group (p = 1 × 10−5)
were decreased after seroconversion (ESM Fig. 6).
Polar metabolites of immune cells in progression to islet auto-
immunity and type 1 diabetes We analysed polar metabolites
from PBMCs from the same samples as in the lipidomic analyses
(ESM Table 2). Using sPLS-DA and univariate analyses, as for
Table 1 Demographic and clini-
cal characteristics of the study
population
Characteristic CTRL P1Ab PT1D
Number of participants 10 27 34
Sex (male, female) (n) (6, 4) (16, 11) (10, 24)
Age at time of diagnosis (months, median ± SD) – – 53.0 ± 30.48
Age of first seroconversion (months, median ± SD) – 24.0 ± 20.12 14.0 ± 6.13
HLA riska (n)
High risk 3 3 6
Moderate risk 1 14 17
Low or neutral risk 6 10 11
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the lipidomic analyses, 25 polar metabolites were altered (sPLS-
DA: AUC ~0.60, RC (>±0.05), VIP scores >1 [40]) and/or
(unpaired two-sample t test, p value <0.05) between the study
groups (P1Ab vs CTRL, PT1D vs CTRL, PT1D vs P1Ab), at
12, 24 and 36 months of age (Fig. 2a). These metabolites can be
divided into major chemical classes, including carboxylic acids,
amino acids, sugar derivatives, hydroxy acids, phenolic
compounds, fatty acids and phosphate derivatives. The log
mean intensities of alanine and glutamic acid in the PT1D,
P1Ab and CTRL children across different age groups are
shown in Fig. 2b and d. Likewise, time was not explicitly
considered for statistical analysis, as the follow-up samples from
all the participants were not available at all the time points.
At 12 months of age, the majority of the polar metabolites
were downregulated in the P1Ab and PT1D groups compared
with the CTRL group. At 24 months, there was an increase in
the levels of several amino acids including alanine, phenylalanine,
proline, serine, threonine, cystine, lysine, glutamic and aspartic
acid in the P1Ab and PT1D groups (Fig. 2a, c).
At 36 months of age, i.e. after seroconversion in most children
in the PT1D and P1Ab groups, an increase in several saturated
fatty acid levels, including stearic, myristic and palmitic acids,
was observed in the PT1D group vs the P1Ab group (Fig. 2a).
Comparing metabolite levels (ESM Fig. 7) before and after sero-
conversion, glutamic acid was found to be decreased (p= 0.008)
after seroconversion in the P1Ab group (Fig. 2e).
Metabolic associations between immune cells and circulating
metabolome Next, we set out to examine how the metabolite
profiles of PBMCs associated with their corresponding plas-
ma profiles. We performed correlation analysis between the
metabolites that were altered in the PBMCs across the three
study groups (Figs 1, 2), with their corresponding plasma
levels, which have previously been reported [16, 41]. These
two previous studies were on an expanded group of individ-
uals, a subsample of which was included in the present study.
In the CTRL group, at 12 months of age, the levels of PCs,
LPCs, SMs and TGs in PBMCs were positively correlated
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Fig. 1 Lipid profiles in PBMCs during follow-up. (a) Log2 fold changes
(FCs) of lipid levels in P1Ab vs CTRL, PT1D vs CTRL and PT1D vs
P1Ab at 12, 24 and 36 months of age. † denotes changes in lipid levels
between the groups (sPLS-DA: AUC ~0.65, RC >±0.05, VIP scores >1
[40]); and unpaired two-sample t test: p value <0.05), as evaluated by
univariate and multivariate analyses; * denotes changes (p < 0.05) in lipid
levels between groups, as evaluated by univariate analysis (unpaired two-
sample t test) only. Red, blue and white colour spectrum signifies up-,
downregulation and no change, respectively. CE, cholesterol ester; PI,
phosphatidylinositol. (b) Log2 mean intensities of Cer(d18:1/24:0) across
different age groups. Loess regression was used for the interpolation of
the data points. The number of participants (‘n’) of a particular group, at a
particular age included in this analysis is shown in ESM Fig. 1. (c)
Intensities of total lipids in CTRL, P1Ab and PT1D groups at 12, 24
and 36 months of age. The red dotted line denotes the mean of the popu-
lation. The black dashes in the bean plots represent individual participants
and their corresponding lipid levels, and the extended black lines denote
the groupmean.Mean of the subgroups at a particular age were compared
by ANOVA *p < 0.05. (d, e) Boxplots showing the levels of Cer(d18:1/
24:0) and TG(48:0) in participants (indicated by the blue dots), before and
after the seroconversion. Black horizontal lines in the boxplots indicate
themedian log intensities of Cer(d18:1/24:0) and TG(48:0) in each group,
the boxes represent the first to third quartiles. A paired t test was
performed as a test of significance, *p < 0.05
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(Spearman’s correlation coefficient, ρ > 0.70, p < 0.05) with
their corresponding plasma levels (Fig. 3a). Conversely, the
polar metabolites were mostly inversely correlated, except
alanine, glutamic acid and valine. At this same age, we also
found a distinct pattern of PC and TG levels in the PT1D
group. Levels of cellular PCs were positively correlated to
their corresponding plasma levels, as in the CTRL group,
while the same PCs were negatively correlated with specific
plasma TG levels (those with a low carbon number and double
bond count) (Fig. 3b). Likewise, the levels of plasma PCs
were inversely correlated with cellular TG levels. In the
P1Ab group, the association between cellular and plasma
metabolites exhibited a different pattern: cellular levels of
PCs were inversely correlated with their corresponding PC
and TG levels in the plasma (ESM Fig. 8).
However, in contrast, at the age of 36 months, the lipid
profiles of PBMCs were predominantly positively correlated
with their corresponding plasma levels in both the PT1D and
P1Ab groups (ESM Figs 8 and 9). These associations were
markedly different in the CTRL group, where predominantly
inverse correlations between cellular and plasma lipids were
observed, except in the case of the majority of the TGs (ESM
Fig. 9).
Over-representation of metabolic pathways in progression to
type 1 diabetes The lipids and polar metabolites of PBMCs
which differed between the three study groups were mapped
against reference human metabolic pathways. The over-
represented metabolic subsystems/processes (e.g. glycerolipid
metabolism, pyruvate metabolism) were selected based on a
false discovery rate (FDR) of <0.05. The pathway impact
score (PIS) was estimated for each subsystem (Fig. 4).
Various core metabolic processes were over-represented in
the immune cells in the PT1D and/or P1Ab groups (vs CTRL)
at 12 months of age, i.e. preceding islet seroconversion and
overt type 1 diabetes. These include central carbon metabolism
(CCM; e.g. glycolysis, citrate cycle), sugar metabolism, amino
acid biosynthesis (valine, leucine and isoleucine;
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Fig. 2 Polar metabolite profiles in PBMCs during follow-up. (a) Log2
fold changes (FCs) in the levels of the polar metabolites in P1Ab vs
CTRL, PT1D vs CTRL and PT1D vs P1Ab groups at 12, 24 and
36 months of follow-up; † denotes changes in the metabolite levels
between the groups (sPLS-DA: AUC ~0.65, RC >±0.05, VIP scores >1
[40]), and unpaired two-sample t test: p < 0.05), as evaluated by univar-
iate and multivariate analyses; * denotes changes (p < 0.05) in the metab-
olite levels between groups, as evaluated by univariate analysis (unpaired
two-sample t test) only. Red, blue and white colours signify up-, down-
regulation and no change respectively. (b) Log2 mean intensities of
alanine in the CTRL, P1Ab and PT1D groups across different age groups
during follow-up. Loess regression was used for the interpolation of the
data points. The number of participants (‘n’) of a particular group, at a
specific age included in this analysis is shown in ESM Fig. 1. (c) Log2
intensities of total polar metabolites as measured in CTRL, P1Ab and
PT1D groups at 12, 24 and 36 months of age. The red dotted line denotes
the mean of the population. The black dashes in the bean plots represent
individual participants and their corresponding levels of total metabolites.
The extended black line denotes the group mean. Mean of the subgroups
at a particular age were compared by ANOVA. (d) Log2 mean intensities
of glutamic acid in the CTRL, P1Ab and PT1D groups across different
age groups during follow-up. Loess regression was used for the interpo-
lation of the data points. The number of participants (‘n’) of a particular
group, at a specific age included in this analysis is shown in ESM Fig. 1.
(e) Levels of glutamic acid in each participant (indicated by the blue dots),
before and after seroconversion; **p < 0.01). Black horizontal lines in the
boxplot indicate the median log intensity of glutamic acid in a group, the
boxes represent the first to third quartiles. A paired t test was performed as
a test of significance
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ph eny l a l a n i n e , t y r o s i n e and t r yp t oph an ) and
glycerophospholipid (GPL) metabolism (Fig. 4). Other
metabolic subsystems such as alanine, aspartate and glutamate
metabolism (AAG) (PIS ~0.4), sphingolipid metabolism
(SMM) (PIS ~0.3), GPL metabolism (PIS ~0.15), arginine
and proline metabolism (PIS ~0.25), and aminoacyl-tRNA
biosynthesis (PIS ~0.2) were over-represented in the P1Ab
and PT1D groups (vs CTRL) at 24 months of age. Moreover,
SMM, GPL, AAG, CCM, glycine, serine and threonine (GST)
metabolism were either over-represented in P1Ab and/or PT1D
groups (vs CTRL) at 36months of age. Interestingly, at this age,
AAG, aminoacyl-tRNA biosynthesis and fatty acid biosynthe-
sis were exclusively over-represented in the PT1D group (vs
P1Ab) (Fig. 4).
Metabolic modelling of sphingolipid metabolism in islet auto-
immunity and type 1 diabetes Given that (1) in our previous
study, we observed persistent downregulation of plasma
sphingolipids in children who progressed to type 1 diabetes
[16, 42], (2) in the present study, SMM was over-represented
in PBMCs isolated from the PT1D, and (3) we recently found
that prenatal chemical exposure modulates postnatal SM
levels and increases type 1 diabetes risk [9], we examined
SMM in PBMCs using genome-scale metabolic modelling
(ESM Fig. 10). The objective of metabolic modelling, in this
case, was to identify the key regulators within SMM in
progression to type 1 diabetes. This extended analysis was
performed by integrating publicly available transcriptomics
datasets obtained from the two related cohorts and the meta-
bolomics dataset from the present study (see Methods). By
using the metabolomics dataset from the present study, we
devised a confidence score for each metabolic reaction as
being either present or absent in the PBMC metabolic model
[38]. The model constraints for exchange/input reactions were
derived using metabolomics data from the present study.
Reporter metabolite (RM) [43] analysis showed that
glucosyl-, lactosyl- and galactosylceramides were upregulated
in the PT1D group compared with P1Ab (Fig. 5b) and CTRL
(ESM Fig. 11). These changes were, however, not observed
when comparing the P1Ab group with the CTRL group.
Instead, LTB4, HETE and EpOME derivatives (all leukotrienes
and markers of inflammation) were upregulated (ESM Fig. 12).
GSMM of SMM suggests that, in the PT1D group, cellular
ceramides are converted to glycoceramides, thus decreasing
the free ceramides in the cells. In order to confirm these find-
ings, we identified and analysed six glycoceramides from the
lipidomics dataset: HexCer(d18:1/16:0), HexCer(d18:1/22:0),
HexCer(d18:1/24:0), LacCer(d18:1/12:0), LacCer(d18:1/
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Fig. 4 Overrepresentation
analysis of metabolic pathways in
PBMCs in CTRL, P1Ab and
PT1D groups. The plot shows the
PIS (false discovery rate [FDR]
<0.05) of each metabolic
subsystem/pathway during
follow-up. Red, green and yellow
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14:0), LacCer(d18:1/16:0). At 36 months of age,
HexCer(d18:1/16:0) and HexCer(d18:1/22:0) were found to
be upregulated (p < 0.05) in the PT1D group vs the P1Ab
group (Fig. 6). There was congruence between the predicted
RMs (Fig. 5b) and the glycoceramide levels measured in the
PT1D group at 36 months of age. At this age, the ceramides
[i.e. Cer(d18:1/24:0) and Cer(d18:1/22:0)] were downregulat-
ed in the PT1D vs the P1Ab group (Fig. 1a).
In order to understand the significance of glucosyl-,
lactosyl- and digalactosylceramide production, we optimised
two key cytoplasmic reactions in SMM, namely, production
of glucosylceramides from ceramides and D-glucose (ESM
Fig. 13) and formation of digalactosylceramide from N-acyl-
sphingosine and D-galactose in the three study groups, and
thereby recorded the flux changes across the different meta-
bolic subsystems/pathways (ESM Fig. 13). The results
suggest that, among several affected metabolic processes,
mitochondrial and endoplasmic reticulum transport of
substrates might be essential for glycoceramide production.
In addition, marked changes in GPL, glycolysis/
gluconeogenesis and amino acid metabolism were observed.
Discussion
We observed metabolic differences in the PBMCs isolated
from PT1D, P1Ab and CTRL children. In line with the previ-
ous findings in plasma [16, 17, 42, 44], these differences were
observed even before the first appearance of islet
autoantibodies.
During the first year of life, i.e. before the median age of
seroconversion, the majority of lipids and polar metabolites
measured in PBMCs were downregulated in the P1Ab and
PT1D groups compared with the CTRL group. The
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Fig. 6 Beanplots showing the levels of hexosylceramides (HexCer) and
lactosylceramides (LacCer) in PBMCs. (a–f) Levels of glycoceramides in
the CTRL, P1Ab and PT1D groups at 12, 24 and 36 months. The red
dotted line denotes themean of the population. The black solid lines in the
bean plots represent the group mean. *p < 0.05, **p < 0.01 by unpaired
two-sample t test. The number of participants (‘n’) of a particular group,
at a particular age included in this analysis is shown in ESM Fig. 1
Fig. 5 Regulation of sphingomyelin pathways in progression to islet
autoimmunity and overt type 1 diabetes. (a) Canonical pathways of
sphingolipid metabolism in humans. C1PP/C1PPase, ceramide-1-
phosphate phosphatase; CDase, ceramidases; CerS, ceramide synthase;
CK, ceramide kinase; DAG, diacylglycerol; DES, dihydroceramide
desaturase; GalCDase, galactosidase; GalCS, galatosylceramide
synthase; GCDase, glucosidase; GCS, glucosylceramide synthase;
KSR, 3-keto dihydrosphinganine reductase; PC, phosphatidylcholine;
S1P lyase, sphingosine-1-phosphate lyase; S1PPase, sphingosine
phosphate phosphatases; SK, sphingosine kinase; SMase,
sphingomyelinase; SMS, sphingomyelin synthetase; SPT, serine
palmitoyl-CoA transferase. (b) RMs predicted for PBMCs that were
significantly different (false discovery rate [FDR] <0.05) between
PT1D and P1Ab groups. The orange and cyan colours denote up- and
downregulation of the RMs, respectively. The cellular compartments
‘[c]’, ‘[g]’, [r]’, ‘[l]’ denote the cytosol, Golgi apparatus, endoplasmic
reticulum and lysosome, respectively
Diabetologia (2020) 63:1017–1031 1027
occurrence of low levels of TGs of low double bond count and
carbon number (i.e. TGs enriched with saturated fatty acids
such as palmitate and myristate) suggest an impairment of de
novo lipogenesis in PBMCs as being potentially involved in
progression towards clinical type 1 diabetes.
At 24 months, i.e. a period coinciding with seroconversion
in the majority of children in the PT1D and P1Ab groups,
there was an increase in the levels of lipids and amino acids
in the PBMCs compared with the control group. There is
evidence that amino acids, in particular, branched chain amino
acids (BCAAs), contribute to dysregulated lipid metabolism
[45]. We observed higher levels of BCAAs and related metab-
olites, including glutamic acid and alanine, in circulating
PBMCs during this period, which is indicative of compro-
mised amino acid catabolism and lipogenesis [46]. In parallel,
elevated BCAAs also promote proinflammatory signalling in
PBMCs [47]. This observed transient increase in BCAAs in
our study suggests that increased BCAAs contribute to
immune dysfunction in children who later progress to type 1
diabetes.
There is growing evidence of abnormal SMM in progres-
sion to and in early type 1 diabetes [48–50]. Differential anal-
ysis of PBMCmetabolites in our study showed changes in the
levels of ceramides and sphingomyelin species in the PT1D
group compared with the CTRL group. Sphingomyelin cleav-
age and ceramide synthesis is one of the important mecha-
nisms involved in the regulation of immune cell function
[51]. Serine and palmitic acid are precursors for de novo
sphingomyelin biosynthesis [52]. We found that serine
concentrations were decreased in type 1 diabetes progressors
after seroconversion. Previous studies by us and others have
also reported decreased plasma levels of SMs in children who
later progressed to type 1 diabetes and in children with newly
diagnosed type 1 diabetes [15, 16, 53]. Our POA provides
corroborating evidence that SMM is over-represented in the
P1Ab and PT1D groups, suggesting that altered SMM in
immune cells, as well as in the circulation, is a hallmark of
progression to overt type 1 diabetes.
GSMM predicted that ceramide pathways leading to
synthesis of glucosyl-, lactosyl- and galactosylceramides were
upregulated in the PT1D group compared with the P1Ab
group. This prediction was confirmed by the observed
increased levels of these glycosphingolipids in the PT1D
group. This strongly implies that ceramides found to be down-
regulated in the PT1D group of our study are converted to
glycoceramides after seroconversion in children who later
progress to type 1 diabetes. In agreement with this, we found
that the gene expression of glucosylceramide synthase (EC
2.4.1.80), a rate-limiting enzyme in the conversion of
ceramides to glucosylceramide and downstream
glycosphingolipids, was also increased. Glycoceramides,
particularly glucosylceramide, play an important role in the
control of immune responses [54]. Previous studies have
shown that these glycosphingolipids modulate beta cell
immune receptor signalling [55, 56] and aggravate systemic
inflammation responses [57, 58]. Elevated glycoceramide
levels in PBMCs in autoantibody-positive children who later
progress to type 1 diabetes, as observed in our study, therefore
point to a specific sphingolipid pathway in immune cells that
contributes to type 1 diabetes pathogenesis.
Of note, the current exploratory study provides a catalogue
of metabolic signatures that are altered in the human PBMCs
obtained from type 1 diabetes progressors and non-
progressors, across different age groups. However, the statis-
tical significance of these markers is yet to be validated in a
larger cohort, with more samples included per age group.
Conclusion and future perspectives
Taken together, our results suggest that progression to type 1
diabetes is accompanied by metabolic abnormalities in
PBMCs. These changes may be related to impaired de novo
lipogenesis, amino acid metabolism, GPL metabolism and
SMM. Since specific differences were also observed between
progressors and non-progressors to type 1 diabetes after their
seroconversion to islet autoimmunity, our findings also high-
light specific pathways in immune cells, such as SMM, which
appear to play an important role in protection from and
progression to type 1 diabetes.
Further mechanistic studies are needed to deconvolute the
metabolic response of immune cell subtypes, particularly
CD4+ and CD8+ T cells, B cells and macrophages that repre-
sent the full repertoire of the PBMCs [12]. It also remains to be
established how the metabolic pathways identified in this
study are altered in specific immune cell subtypes, and wheth-
er a targeted manipulation of these pathway(s) can suppress an
excessive immune response, which, in turn, might retard the
onset and/or progression of type 1 diabetes.
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